Remdesivir for the Treatment of Covid-19 - Final Report.
John H BeigelKay M TomashekLori E DoddAneesh K MehtaBarry S ZingmanAndre C KalilElizabeth HohmannHelen Y ChuAnnie LuetkemeyerSusan KlineDiego Lopez de CastillaRobert W FinbergKerry DierbergVictor TapsonLanny HsiehThomas F PattersonRoger ParedesDaniel A SweeneyWilliam R ShortGiota TouloumiDavid Chien Boon LyeNorio OhmagariMyoung-Don OhGuillermo M Ruiz-PalaciosThomas BenfieldGerd FätkenheuerMark G KortepeterRobert L AtmarC Buddy CreechJens LundgrenAbdel G BabikerSarah PettJames D NeatonTimothy H BurgessTyler BonnettMichelle GreenMat MakowskiAnu OsinusiSeema NayakHenry Clifford Lanenull nullPublished in: The New England journal of medicine (2020)
Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.).